Short answer
Oncology Institute, Inc. (TOI) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $170M (up 24.3% year over year) with net income of −$16M.
Q3 2026 key financials · XBRL
- Revenue
- $170M
- +24.3% YoY · +5.3% QoQ
- Net income
- −$16M
- +4.6% YoY · −60.9% QoQ
- Operating margin
- -1.8%
- EPS (diluted)
- −$0.13
- +7.1% YoY · −62.5% QoQ
Source: XBRL data from the Oncology Institute, Inc. (TOI) Q3 2026 10-Q on SEC EDGAR. USD.
Oncology Institute, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $169.8M, up 24.3% YoY from $136.6M
- Net loss margin 9.2% vs 12.2% YoY, operating loss margin 1.7% vs 6.0%
- Best segment, Specialty Pharmacy revenue $109.3M, up 44.0%; patient services $60.0M, down 0.3%
- Cash $36.9M, operating cash flow $19.9M, senior secured term-loan proceeds $75.0M
- Near-term liquidity sufficient for at least one year, with $134.5M in material cash requirements disclosed
Risk Factors
- No material changes to previously disclosed risk factors in the December 31, 2025 Form 10-K
- Carried-forward risks include assumptions, uncertainties, and other factors that could adversely affect business performance
- Future SEC filings may disclose changes to existing risks or additional risk factors
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Oncology Institute, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.